Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial

Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial

Davey, R. T., Collins, G. L., Rouphael, N., Poliquin, G., McConnell, R., Grubbs, G., Moir, S. L., Langley, J. M., Teitelbaum, M., Hewlett, A. L., McLellan, S. L. F., Bhadelia, N., Raabe, V. N., Mulligan, M. J., Maljkovic Berry, I., Dighero-Kemp, B., Kurtz, J. R., Hensley, L. E., Dozier, N. C. E. & Marron, L. C. B. & 6 others, DuChene, A., Kuhn, J. H., Brown, S. K., Khurana, S., Lane, H. C. & Neaton, J. D., Nov 2024, In: The Lancet Microbe. 5, 11, 100923.

Research output: Contribution to journalArticlepeer-review